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Chronic pulmonary infection with Pseudomonas aeruginosa is a feature of cystic fibrosis (CF) and other chronic lung diseases.
Cytokines of the interleukin-17 (IL-17) family have been proposed as important in the host response to P. aeruginosa infection
through their role in augmenting antibacterial immune responses, although their proinflammatory effect may contribute to
lung damage that occurs as a result of chronic infection. We set out to explore the role of IL-17 in the host response to chronic P.
aeruginosa infection. We used a murine model of chronic pulmonary infection with CF-related strains of P. aeruginosa. We
demonstrate that IL-17 cytokine signaling is essential for mouse survival and prevention of chronic infection at 2 weeks postin-
oculation using two different P. aeruginosa strains. Following infection, there was a marked expansion of cells within mediasti-
nal lymph nodes, comprised mainly of innate lymphoid cells (ILCs);90% of IL-17-producing (IL-17) cells hadmarkers con-
sistent with group 3 ILCs. A smaller percentage of IL-17 cells hadmarkers consistent with a B1 phenotype. In lung
homogenates harvested 14 days following infection, there was a significant expansion of IL-17 cells; about 50% of these were
CD3, split equally between CD4 Th17 cells and  T cells, while the CD3 IL-17 cells were almost exclusively group 3 ILCs.
Further experiments with B cell-deficient mice showed that B cell production of IL-17 or natural antibodies did not provide any
defense against chronic P. aeruginosa infection. Thus, IL-17 rather than antibody is a key element in host defense against
chronic pulmonary infection with P. aeruginosa.
Some bacteria have evolved the ability to produce chronic in-fection of the respiratory tract. Mycobacterium tuberculosis is
perhaps the best known example, but the Gram-negative patho-
gen Pseudomonas aeruginosa can also become persistent in the
lower airways. This occurs most notably in patients with cystic
fibrosis (CF) and bronchiectasis but is also increasingly recog-
nized in other chronic lung diseases, such as chronic obstructive
pulmonary disease (COPD). In CF, P. aeruginosa infections are
initially intermittent and can be eradicated by intensive antibiotic
treatment (1). Transition to chronic P. aeruginosa airway infec-
tion usually ensues, such that by age 20, 60 to 70% of CF patients
are chronically infected (2). The continuous presence of P. aerugi-
nosa in the airways is accompanied by an inexorable decline in
respiratory function, leading to premature death or lung trans-
plantation (3). Thus, this switch from intermittent to chronic in-
fection is a key event in the progression of disease (1). Although
antibiotics can delay this transition, better therapies aimed at pre-
venting chronic infection could potentially significantly attenuate
the rate of decline in lung function in patients affected by CF, as
well in other chronic lung diseases in which chronic P. aeruginosa
infection occurs.
Little is known of the mechanisms of host defense against
chronic P. aeruginosa infection. Cytokines of the interleukin-17
(IL-17) family have been suggested as important in protection
against P. aeruginosa infection. IL-17 in the lung may be impor-
tant in host defense against P. aeruginosa through its ability to
orchestrate a neutrophil response and by the induction of a variety
of innate antimicrobial peptides (4). Increased levels of IL-17A
(hereinafter referred to as IL-17) are found in sputum and bron-
chial lavage specimens of patients with CF (5), produced by a
variety of cells of the innate and acquired immune system, includ-
ing T cells of the Th17 lineage (6–9).Other cells known to produce
IL-17 include, inter alia, innate lymphoid cells (ILCs),  T cells,
and natural killer (NK) cells. Although such inflammatory re-
sponses can contribute to host defense, they also can potentially
cause tissue damage, as is well known forM. tuberculosis infection,
where the host inflammatory response can result in significant
tissue damage. Proinflammatory actions of IL-17 in P. aeruginosa
infection could increase tissue damage through excess neutrophil
accumulation and induction of matrix metalloproteinases (10).
Indeed, the inflammatory changes and subsequent bronchiectasis
so typical of CF have been suggested to be driven by IL-17 cyto-
kines. Although one study examined the role of IL-17 in acute
infection (11), the specific role of IL-17 in chronic P. aeruginosa
infection has not been addressed.
In the work presented here, we have defined the interactions
and effector functions of the IL-17 axis in the pathogenesis of
chronic pulmonary P. aeruginosa infection. Using a murine
model, we show that IL-17 signaling is crucial in host defense
against chronic P. aeruginosa infection, protecting against chronic
colonization and death. Despite increased bacterial burdens, mice
lacking IL-17 signaling had less weight loss than controls. We
identified a diverse range of cellular sources of IL-17 both in drain-
ing mediastinal lymph nodes and in lungs following infection.
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MATERIALS AND METHODS
Agar bead infection model. The infection model was adapted from the
protocol described by vanHeeckeren and Schluchter (12) andmodified as
described previously (13). Pseudomonas aeruginosa-laden agar beads were
prepared the day before inoculation and stored overnight at 4°C, and a
different bead preparation was used for each experiment. P. aeruginosa-
laden beads were stored on ice throughout the murine surgery. Following
inoculation of P. aeruginosa-laden beads, the inoculum administered was
confirmed by homogenization and quantitative bacteriology of a further
two aliquots of beads. Sterile agar beads were stored at 4°C and used for
several experiments. Sterile agar bead preparations were confirmed to be
sterile before and after each use. For experiments using knockout mu-
tants, all animals (knockout mutants and wild-type [WT] controls) were
treated with P. aeruginosa-laden beads. In separate experiments,WTmice
were treated with either P. aeruginosa-laden or sterile agar beads.
For inoculation with P. aeruginosa-laden beads, mice were anesthe-
tized using isoflurane via nose cone, and the trachea was exposed and
cannulated (22-gauge intravenous cannulae; BDBiosciences) under asep-
tic conditions. An average inoculum of 1 106 CFU/50l per mouse was
delivered. Animals were closelymonitored postoperatively using a disease
severity scoring system (see Table S1 in the supplemental material). An
animal reaching a moribund endpoint was euthanized.
Surviving animals at 14 days after infection were culled; lungs were
removed from some and mechanically homogenized, and aliquots plated
on bacteriologicalmedium to determine the numbers of CFUofP. aerugi-
nosa. Chronicity rates were defined as the percentages of animals at 14
days after infection that had viable P. aeruginosa cells recovered from their
lungs using this method.
Flow cytometry. Antibodies to the following were used for flow cy-
tometry: CD3e (145-2C11; eBioscience and BioLegend); CD19 (eBio1D3
[eBioscience] and 6D5 [BioLegend]); CD4 (GK1.5), CD5 (53-7.3),
CD11c (N418), CD23 (B3B4), CD43 (eBioR2/60),  T cell receptor
(-TCR) (UC7-13D5), gamma interferon (IFN-) (XMG1.2), IgD (11-
26c), and IgM (II/41) (all from eBioscience); CD45R/B220 (RA3-6B2),
granulocyte-macrophage colony-stimulating factor (GM-CSF) (MP1-22E9),
Gr-1 (RB6-8C5), and IL-17A (TC11-18H10.1) (all from BioLegend); and
IL-22 (3F11; Genentech). Isotype controls were used to confirm the spec-
ificity of staining. For intracellular staining, cells were polyclonally stim-
ulated with 50-ng/ml phorbol myristate acetate (PMA) and 500-ng/ml
ionomycin in the presence of brefeldin A (BD GolgiPlug at 1 g/ml) at
37°C for 5 h, fixed using 4% paraformaldehyde (Thermo Scientific) in
phosphate-buffered saline (PBS) for 10 min at 4°C, and then washed in
fluorescence-activated cell sorting (FACS) buffer (PBS, 2% fetal calf se-
rum [FCS], 0.09% sodium azide [Sigma-Aldrich]). Cells were permeab-
ilized using PermWash buffer (BD Biosciences) prior to staining. Dead
cells were detected by using eFluor506 (eBioscience). For neutrophil
quantification via flow cytometry, CountBright absolute counting beads
(Invitrogen) were added prior to washing cells and used according to the
manufacturer’s instructions. Stained cells were analyzed using a FACSAria
instrument (BD Biosciences) and FlowJo software (TreeStar).
P. aeruginosa strains. The clinical NH57388A strain was provided by
N. Hoffmann (University of Copenhagen). This strain possesses a muta-
tion inmucA that results in hyperproduction of alginate (14). Themucoid
YH5 strain and nonmucoid GRI-1 strain were obtained locally, from a
patient with CF and a patient with ventilator-associated pneumonia, re-
spectively. P. aeruginosa strains were maintained in 80°C stocks until
required. Prior to use in cell culture, each strain was grown to mid-log
phase in Luria-Bertani (LB) broth (Invitrogen) and bacterial concentra-
tions at an optical density at 600 nm (OD600) of between 0.4 and 0.6 were
quantified by serial dilution and plating to enumerate CFU (GeneQuant
Pro spectrophotometer; Amersham Biosciences). Heat-killed P. aerugi-
nosa preparations were produced by heating a known concentration of P.
aeruginosa in PBS to 95°C for 10 min.
Cytokine measurement. Murine IL-17A, IL-17F, IL-21, IL-22, and
IFN- were quantified by enzyme-linked immunosorbent assays (ELISAs)
(all eBioscience). The lower limits of detection were 4 pg/ml for
IL-17A, 15pg/ml for IL-17F, 16 pg/ml for IL-21, 8 pg/ml for
IL-22, and 15 pg/ml for IFN-. Cytokine levels below the lower
limits of detection of the assay were assigned a value of zero.
Immunochemistry andhistology scoring.Lung sectionswere stained
with brilliant violet 421 anti-B220 antibody (clone RA3-6B2; Biolegend)
and anti-CD90.2 antibody (Thy1.2) (clone 53-2.1; Biolegend) conjugated
with Alexa Fluor 488-streptavidin (both at a concentration of 1:50).
SYTOX green nuclear stain (Invitrogen) was used at a concentration of
1:10,000. The histology scoring system used is shown in Table S2 in the
supplemental material.
Animals. All mice were used between 12 and 16 weeks of age. IL-17A
receptor (IL-17RA) knockoutmice (15)were fromT.Mitchell, University
of Glasgow, and originally supplied by Jay Kolls; MT mice (16) were
from R. Nibbs, University of Glasgow. Each of these lines was on a
C57BL/6 background. C57BL/6 mice bred in-house were used as wild-
type controls for knockout comparisons. The animalworkwas carried out
under a project license as required by United Kingdom Home Office
regulations, as well as scrutiny and approval by an institutional review
board.
Ethics. The animal studies were approved by the granting of a project
license from the United KingdomHomeOffice, aministerial government
department that oversees all experimental work with animals in the
United Kingdom. The project license number is 60/4361. This work was
also reviewed and approved by the University of Glasgow AnimalWelfare
and Ethical Review Board, under the same license number.
Mediastinal lymph node, splenocyte, and peritoneal B1a cell stimu-
lation.Mediastinal lymph nodes and spleens were passed through 80-m
Nitex mesh and red blood cells (RBCs) lysed (RBC lysis buffer; Sigma-
Aldrich) to form a single-cell suspension. Cells were either left unstimu-
lated or stimulated with heat-killed P. aeruginosa at a multiplicity of in-
fection (MOI) of 30. Following 3 days of culture, 100 l of supernatant
was removed for cytokine and P. aeruginosa-specific antibody quantifica-
tion, and cells prepared for flow cytometry.
Lung homogenate, BALfluid, and pleural wash samples. Lung tissue
was agitated for 1 h at 37°C with 10 g/ml DNase (Roche) and 0.65
units/ml Liberase (Roche), passed through 80-mNitex mesh, and RBCs
lysed to obtain a single-cell suspension. Bronchoalveolar lavage (BAL)
fluid and pleural wash samples underwent RBC lysis. Cells were then
prepared for flow cytometry.
P. aeruginosa-specific immunoglobulin quantification. The ELISA-
based method of detecting P. aeruginosa-specific IgM and IgG was
adapted from themethod ofMoser et al. (17). Bound antibody was quan-
tified by detection of biotinylated goat anti-mouse IgM (mu chain spe-
cific; Vector Laboratories) or anti-mouse IgG (Fc specific; Sigma-
Aldrich).
Sequence analysis. Genomes were compared using progressive-
Mauve.
Statistics. Results are presented as median values or, for technical
repeats, mean values and standard errors of the means (SEM). Nonpara-
metric statistical tests were used (Mann-Whitney, Kruskal-Wallis, and
where appropriate, Dunn’s multiple-comparison tests). For parametric
testing, Student’s 2-sample t test was used. Comparisons of animal weight
changes were analyzed using repeated-measures ANOVA. Statistical anal-
ysis was undertaken using Prism version 6.0 (GraphPad Software). A P
value of0.05 was considered significant.
RESULTS
Establishment of a model of chronic pulmonary infection with
P. aeruginosa. We adapted the well-established agar bead model
of P. aeruginosa infection in mice (18, 19). We used two different
clinical strains of P. aeruginosa from patients with CF: YH5, a
mucoid isolate, and NH57388A (14), a highly mucoid strain of P.
aeruginosa that carries a mutation in the mucA gene, resulting in
alginate overproduction, a common phenotypic change in P.
Bayes et al.
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aeruginosa isolates following chronic infection of the airways in
CF patients (20). We performed draft whole-genomic sequencing
of the YH5 strain and compared its sequence with the published
sequences of the type strain, PAO1 (21), and NH57388A (22).
Comparison of the whole genomes (see Fig. S1A in the supple-
mental material) shows the typical pattern of strain differences in
this species, with blocks of highly conserved sequences inter-
spersedwith regions of insertions or deletions; note that a segment
of the NH57388 genome is inverted relative to the sequence of
PAO1. Of the many differences, a notable one is the disruption in
NH57388 of themucA gene (see Fig. S1B), which encodes an anti-
sigma factor that is responsible for the mucoid phenotype of this
strain (14). This gene is retained in PAO1 and YH5. Another sig-
nificant difference is the loss of some of the genes of the phenazine
biosynthesis pathway in YH5 (see Fig. S1C). This pathway is es-
sential for the synthesis of pyocyanin, an important virulence fac-
tor for P. aeruginosa (23). These differences are considered further
in Discussion.
Following transtracheal delivery of P. aeruginosa-laden beads,
virtually all animals recovered completely after anesthesia (4 fatal-
ities within 1 h in 300 procedures). YH5-infected animals re-
mained well for the 14-day period of each experiment, with no
differences in clinical score between animals that were given P.
aeruginosa-laden beads and those given sterile beads. However,
weight loss following bead delivery was significantly greater in
mice given the YH5 P. aeruginosa-laden beads than in those re-
ceiving sterile beads (24). Following NH57388A inoculation,
there were various amounts of early mortality (4 days), between
0 and 40%. Surviving animals remained well. No animals devel-
oped bacteremia following pulmonary infection. At 2 weeks fol-
lowing delivery of beads, NH57388A infection resulted in a mean
chronicity rate of 43.4% (standard deviation [SD], 23.9%, and
range, 11.1 to 71.5%, for results from 5 experiments with 7 to 10
surviving animals/group). The YH5 strain resulted in a mean
chronicity rate of 18.82% (SD, 20.54%, and range, 0 to 37.5%, for
results from 6 experiments with 7 to 14 surviving animals/group)
at 14 days postinoculation.
As a measure of the inflammatory response following infec-
tion, we enumerated neutrophil numbers in BAL fluid samples 2
weeks following infection (see Fig. S2 in the supplemental mate-
rial) (13). These results showed that animals with viable bacteria
within their lungs at 2 weeks following infection had significantly
elevated levels of neutrophils within their BAL fluid samples com-
pared to the levels in BAL fluid samples from animals that had
received sterile beads or those that had cleared the infection.
The bacterial colony counts in chronically infected animals at 2
weeks after infection were very similar for NH57388A and YH5
(see Fig. S3a in the supplemental material); lung homogenates
from animals receiving sterile beads contained no organisms. A
notable feature of NH57388A P. aeruginosa colonies recovered
from the lungs of chronically infected animals was the appearance
of many small-colony variants (see Fig. S3b); this is a common
phenotypic variant found in clinical P. aeruginosa isolates and is
associated with greater biofilm formation and antibiotic resis-
tance. These small-colony variants were present in over 80% of
chronically infected animals and could be seen as early as 4 days
after infection. Small-colony variants were not seen following in-
fection with the YH5 strain.
Use of the GRI-1 strain, recovered from a patient with ventila-
tor-associated pneumonia, resulted in marked hemorrhagic
pneumonia with death of the infected animals with 24 h, and thus,
this strain was not used further in our animal models of chronic
infection.
IL-17RA-dependent signalingmediates resistance to chronic
infection with P. aeruginosa. We compared the responses to P.
aeruginosa infection between wild-type (WT) animals and mice
lacking the IL-17RA receptor chain that mediates IL-17 family
actions (25). Following inoculation with the YH5 P. aeruginosa
strain, the infection rates 2 weeks later were 25% inWT animals (5
out of 20 animals) and 100% in IL-17RAknockoutmice (20 out of
20 animals), a highly significant difference (P  0.0001, Fisher’s
exact test). The pulmonary bacterial loads were significantly in-
creased in the IL-17RA knockout animals at 2 weeks following
infection (Fig. 1a), but none of the infected animals died or be-
came bacteremic. In striking contrast to the results of infection
with the YH5 strain, infection of IL-17RA knockout animals with
the NH57388A P. aeruginosa strain resulted in the death of all
infected animals within 3 days of infection (Fig. 1b), a statistically
significant difference fromWT littermates.
All YH5-infected animals, including the subgroup that became
chronically colonized, showed an initial drop in weight (Fig. 1c).
However, IL-17RA knockoutmice showed a smaller initial weight
loss and early recovery of their starting weight after infection, a
significant difference from the WT animals (Fig. 1c).
Leukocyte, cytokine, and histological responses following
infection. In wild-type animals, IL-17A and IL-22 were found at
low levels in BAL fluid both at 48 h (see Fig. S3c and d in the
supplemental material) and 2 weeks (see Fig. S3e and f) following
infection, but there was no significant difference between infected
animals and sterile-bead-treated controls. Surprisingly, compari-
son of IL-17RA knockout and WT mice demonstrated that 2
weeks following infection with the YH5 strain, there was no sig-
nificant difference in absolute neutrophil counts in the BAL fluid
(see Fig. S3g); similar results were found following infection with
the NH57388A strain (data not shown).
Two weeks after infection, animals showed persistent inflam-
matory changes in the lung, with localized peribronchial mono-
nuclear infiltrates, and frequently, an agar bead evident in the
adjacent airway (Fig. 1d and e). Therewas no significant difference
in overall histological scores betweenWT and IL-17RA knockout
mice (Fig. 1g). However, we did observe areas of very extensive
(	50 cells deep) monocytic infiltrates in response to chronic P.
aeruginosa infection in IL-17RA knockout animals (Fig. 1f) that
were never seen in the WT mice.
IL-17A production in P. aeruginosa-specific immune re-
sponses following infection. Two weeks following P. aeruginosa
infection, there was a marked enlargement of the mediastinal
lymph nodes compared to the lymph nodes of control animals
(mean values of 3.56 106 cells for NH57388A-infected animals
versus 2.83 105 cells for sterile-bead-treated animals; three sep-
arate experiments, P  0.05 by t test). Ex vivo restimulation of
these lymphnode cells from infected animals with heat-killed bac-
teria of the infecting strain, NH73788A, or an unrelated clinical P.
aeruginosa strain, GRI-1, for 3 days resulted in robust production
of IL-17A, which was not evident in the lymph node cells from
animals receiving sterile beads (Fig. 2a). To characterize the cells
producing these cytokines, we stained them for a variety of phe-
notypic surface and intracellular markers. Initially, cells from in-
fected animals were stained for the T cell marker CD3 (Fig. 2b).
Comparisonwith cells stainedwith an isotype control showed two
IL-17 in Chronic Pseudomonal Lung Infection
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populations: a very clear CD3
 population with low side scatter
(Fig. 2b, outlined in black) and a more diffuse population with
lower expression of CD3 (Fig. 2b, outlined in red) that overlapped
considerably with cells stained with the isotype control. We de-
noted these populations as CD3 intermediate-high (CD3int-hi)
and CD3 low-intermediate (CD3lo-int), respectively.
Following restimulation of cells from infected animals with
NH57388A bacteria, there was a marked expansion of CD3lo-int
cells that was not seen in cells from animals that had received
sterile beads (Fig. 2b). There was also an increase in the numbers
of CD3int-hi cells in the nodes of infected animals; these too in-
creased in numbers in response to restimulation, but to a lesser
FIG 1 Responses ofWT and IL-17RA-knockout animals to pulmonary P. aeruginosa infection. (a) Pulmonary bacterial burdens in animals chronically infected
with YH5 at 2 weeks postinfection. Lines indicate median values. P value was determined with the Mann-Whitney test from pooled results of two experiments,
each with 10 mice per group. (b) Kaplan-Meir survival curves of WT (circles) or IL-17RA knockout (KO) animals (squares) infected with the NH57388A strain
(n 10 per group). Significant differences were determined by log rank test; P 0.0092. (c)Weight changes in animals (n 10) remaining chronically infected
at 14 days following infection with the YH5 strain; results are for WT (circles) or IL-17RA KO animals (squares). Each point represents the mean weight at that
time; error bars show SEM. Differences between the groups are significant at a P value of0.0001 by repeated-measures ANOVA. (d, e) Hematoxylin and eosin
(H&E)-stained lung sections from infectedWTmice 2 weeks after infection with YH5 strain. Arrows show agar beads. Scale bars show 100m (d) or 50m (e).
(f) Large (	50 cells deep)monocytic accumulations were observed in lungs from IL-17RAKOmice. Scale bar shows 10m. (g) Histological scores for indicated
animals 2 weeks after infection with YH5 strain. P 0.7266 by Mann-Whitney test.
Bayes et al.
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FIG 2 Immune responses following P. aeruginosa infection. Two weeks after infection, mediastinal lymph node cells from WT mice treated as indicated were
stimulated ex vivo with heat-killed P. aeruginosa strains (MOI of 30) or left unstimulated for 3 days. (a) Levels of IL-17A secretion are shown; bars show mean
values and error bars show SEM. **, significantly different from sterile beads at a P value of0.01 by t test; Un, unstimulated; NH, NH57388A. Representative
results from three separate experiments are shown. (b) Flow cytometry results for stimulated (3 days) mediastinal lymph node cells stained as shown. The
CD3lo-int populations are outlined in red, and the CD3int-hi populations are outlined in black. The total number of cells recovered in each gate is shown next to
the gate. SSC, side scatter. (c to e) Flow cytometry of lymph node cells as described in the legend to panel B except that cells were gated on theCD3int-hi population
(c), the CD3lo-int population (d), or as indicated (e). The percentage of cells in each quadrant is shown. (f) Fold increases in P. aeruginosa-binding IgM and IgG
produced bymediastinal lymph node cells from infected animals restimulatedwith P. aeruginosa strains ex vivo compared to the levels produced by unstimulated
cells. Columns represent mean values for triplicate wells; error bars show SEM. Columns were compared to a theoretical mean of 1.0 by Student’s t test. NS,
nonsignificant; *, P 0.05; **, P 0.01.
IL-17 in Chronic Pseudomonal Lung Infection
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extent than the CD3lo-int population (Fig. 2b). There was very
limited expression of IL-17A or IFN- within the CD3int-hi popu-
lation (Fig. 2c). However, in the CD3lo-int population, there was a
significant population of both IL-17A- and IFN--producing cells
(Fig. 2d), predominantly frommediastinal lymph node cells of P.
aeruginosa-infected animals rechallenged with the infecting P.
aeruginosa strain ex vivo. The percentage of restimulated cells pro-
ducing IL-17A that were in the CD3lo-int population was 98% of
the combined (CD3lo-int and CD3int-hi) population.
We analyzed the IL-17 production within this CD3lo-int popu-
lation further. Approximately 90% of these cells making IL-17
were also negative for the B cell markers CD19 and B220 (Fig. 2e),
consistent with innate lymphoid cells (ILCs) of the group 3 family
(ILC3). However, 5 to 10% of this CD3lo-int IL-17
 population
were reproducibly positive for both of these B cell markers (Fig.
2e). Over 90% of these CD3lo-int CD11c (a dendritic cell marker)
B220
 CD19
 IL-17
 cells were positive for CD5 (see Fig. S4 in
the supplemental material), consistent with a B1a population
(26). Further characterization of the CD3lo-int CD19mediastinal
lymph node cells expressing IL-17 showed that very few expressed
GM-CSF. Over 60% of the CD3lo-int- CD19 cells expressed
IFN-, but coexpression of IL-17 and IFN- was only seen in a
minority of these cells (Fig. 2e). The IL-17
CD3lo-int CD19 cells
were also essentially negative for the dendritic cell marker CD11c
(Fig. 2e) and the NK cell marker NK1.1 (data not shown). Taken
together, these data show that the large expansion of cells within
the mediastinal lymph nodes 2 weeks following infection with P.
aeruginosawas largely composed of cells with the characteristics of
ILCs; those expressing IL-17 belong to the group 3 ILC family
(27–29). This is considered further in Discussion.
We analyzed P. aeruginosa-specific immunoglobulin produc-
tion from the mediastinal lymph node cells. We detected five- to
ninefold increases in P. aeruginosa-reactive IgMbut not IgG in the
supernatants from restimulated lymphnode cells compared to the
levels in supernatants from unstimulated cells (Fig. 2f). This was
observed for the ex vivo response of lymph node cells to both the
infecting strain, NH57883A, and an unrelated strain, GRI-1.
Importantly, we adopted a strict gating strategy to exclude
“doublets,” which might otherwise result in the inclusion of T-B
cell couples positive for B cell markers, such as B220 and CD19.
This removed doublets on the basis of their increased pulse width
relative to the side-scatter area (see Fig. S5a to c in the supplemen-
tal material) (30). In addition, all analyses were performed under
conditions that minimize doublet formation, including the use of
cell densities of less than 106 cells/ml, less-than-maximal flow
rates, and vortexing of cells prior to the analysis (30). All analyses
were performed using the double gating strategy shown in Fig. S5;
in practice, this made little difference to the percentages of cells
classed as phenotypically B, T, or otherwise.We also evaluated the
CD3 staining properties of B220
 CD19
 cells prior to gating; as
shown by the results in Fig. S5d, the B220
 CD19
 cells (see data
in red in Fig. S5d) showed virtually no overlap with the CD3int-hi
population (see data in blue in Fig. S5d), supporting the distinc-
tion between these populations of cells.
Parenchymal lung cell responses to chronic P. aeruginosa
infection. Next, we examined the potential of cells within lung
tissue to produce IL-17. Lung homogenates showed a significant
increase in total cells expressing IL-17 2weeks following treatment
with P. aeruginosa-laden beads in WT mice (Fig. 3a and b), dis-
tributed equally between CD3
 and CD3 populations (Fig. 3c to
e). The CD3
 IL-17
 population was composed mainly of CD4

(Th17) and  T cells in approximately equal numbers; NK/NKT
cells were not detected (Fig. 3f to h). Themajority of IL-17 expres-
sion from the CD3 population is from non-B (B220) cell
sources, consistent with an innate lymphoid cell population. B
cells constituted 3.83% of the CD3 cells expressing IL-17 (Fig.
3i), with virtually no IL-17 production fromNKcells (Fig. 3j). The
CD3 B220
 population predominantly expressed IL-17 from
the CD43
 subset, consistent with a B1 cell population (Fig. 4a to
d). Lung immunostaining confirmed parenchymal B and T cell
responses in P. aeruginosa-infected animals, demonstrating peri-
bronchial mononuclear B cells (B220
) and more widely distrib-
uted T cells (Thy 1.2
) (Fig. 4e and f).
Response to pulmonary P. aeruginosa infection in B cell-
deficient mice. A small fraction of the IL-17-producing cells in
our model of chronic P. aeruginosa infection were B cells, with
characteristics of innate B1 cells. Innate B cells have been impli-
cated as important in host defense against bacterial infection, both
through their production of natural immunoglobulin that can
bind to bacterial pathogens and through differentiating into GM-
CSF-producing protective cells (31, 32). We addressed the role of
B cells in protection by these mechanisms against chronic P.
aeruginosa infection in our murine model. We infected mice that
lack cells of the B lineage (MT mice) using P. aeruginosa-laden
beads and compared their responses to those of WT animals.
There was no difference in mortality between WT and MT
mice 2 weeks following infection (1 in 13 infected MT animals
died, versus 1 in 18 WT animals; P  1.0 by Fisher’s exact test).
The proportions of animals chronically infected 2 weeks after in-
fection were also not significantly different between the groups (6
of 12MT animals versus 9 of 17WT animals; P 1.0 by Fisher’s
exact test). Furthermore, the pulmonary bacterial burdens in
chronically infected animals were not significantly different be-
tween the groups (Fig. 5). There was no difference between WT
and MT mice for IL-17 production from P. aeruginosa-stimu-
lated mediastinal lymph node cells at 14 days after infection (data
not shown).
DISCUSSION
Here, we have shown that IL-17 family cytokines play a crucial role
in preventing chronic infection of the airways with P. aeruginosa
in a murine model of infection. The change from intermittent to
chronic infection of the airways with P. aeruginosa is a key transi-
tion point in patients with CF; delay of this stage would likely
prolong life expectancy in patients with CF. Thus, enhancing
IL-17 actions at this point in the clinical course of CF could be a
potential therapeutic target.
IL-17 family members have a potent effect on neutrophil pro-
duction and mobilization (15, 33). Although we found small re-
ductions in blood neutrophil counts between WT and IL-17RA
knockout animals before and after infection (data not shown),
there was no difference in BAL fluid neutrophil counts between
these groups of animals following infection. However, pulmonary
neutrophil recruitment may still play a critical role in preventing
chronic infection via a very early IL-17-dependent neutrophil in-
flux. In addition, direct IL-17 activation of neutrophils was re-
cently shown to be required for optimal fungal killing (34). The
protective effect of IL-17 in the pulmonary P. aeruginosa infection
model could also result from the ability of IL-17 to induce anti-
microbial peptides, such as defensins and the S100 proteins; in-
Bayes et al.
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deed, in ocular infections, human-defensin 2 plays an important
role in host defense against P. aeruginosa (35). In addition, IL-17
induces proinflammatory cytokines like IL-6 and tumor necrosis
factor alpha (TNF-). The lack of weight loss seen in infected
IL-17RA knockoutmicemay reflect the lack of such inflammatory
cytokine production, since these cytokines are associated with loss
of body mass (36).
We identified a number of different cellular sources that pro-
duce IL-17 in this model of infection. In the draining mediastinal
lymph nodes following infection, we found a considerable expan-
sion of cells that predominantly had the characteristics of group 3
ILCs. Specifically, given their production of IL-17, these are likely
to be lymphoid tissue inducer (LTi) cells. Further characterization
using the ILC3 markers CD127 and RORt will be required to
establish the identity of these cells beyond doubt. ILC3/LTi cells
have been implicated in host resistance to extracellular bacteria,
chronic inflammation, and tissue repair. Recently, group 3 ILCs
have been shown to present antigen and to contribute to the con-
trol of CD4
 T cell responses to commensal bacteria (37, 38). The
expansion of group 3 ILCs in the mediastinal lymph nodes has
been described previously in a helminth infection model (39).
This study found that in mesenteric lymph nodes, the group 3
ILCs migrated in a CCR7-dependent fashion from the intestine.
The origin of the group 3 ILCs that migrate to mediastinal lymph
FIG 3 Lung parenchymal responses to P. aeruginosa infection. (a) Representative intracellular expression of IL-17A in lung parenchymal cells 2 weeks following
instillation of sterile or P. aeruginosa-laden (strain NH57388A) beads. Numbers show percentages of total cells in ringed areas. (b) Percentages of total lung
parenchymal cells expressing IL-17A 2 weeks after introduction of sterile or P. aeruginosa-laden beads. Each symbol represents an individual animal; lines show
median values. P value was determined byMann-Whitney test. (c) Representative expression of intracellular IL-17A in CD3
 and CD3 populations in lungs 2
weeks following P. aeruginosa infection as assessed by flow cytometry. (d, e) Data are as described in the legend to panel B but show the percentages of CD3
 (d)
and CD3 (e) cells expressing intracellular IL-17A. (f to h) Flow cytometry results for CD3
 IL-17A
 cells expressing the indicated markers; boxed areas are
deemed positive relative to results for isotype controls. Figures show percentages of the total CD3
 IL-17A
 population expressing the indicated markers. (i, j)
Data are as described for panels F to H but with gating on CD3 IL-17A
 cells.
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nodes is not clear, especially as the lung has a very low number of
these cells. The function of these cells in this location is also not
clear. Neutrophils are recruited to regional lymph nodes in infec-
tion and inflammation. In this location, they potentially fulfill a
number of roles, including limiting pathogen escape, modulating
subcapsular sinus macrophage numbers, and influencing den-
dritic cell maturation and antigen presentation (reviewed in ref-
erence 40). IL-17 family cytokines released by group 3 ILCs within
draining lymph nodes would thus be one mechanism whereby
neutrophils could be recruited to this site during an infection.
Further work will be required to explore these possibilities.
We found a small but significant population of B cells that
produced IL-17 in the mesenteric lymph nodes following infec-
tion. B cell production of IL-17 has been found in a model of
Trypanosoma cruzi infection inmice (41). Our study suggests that
B1 cells are a source of this cytokine. B1 cells are the predominant
B cell in pleural and peritoneal compartments and continuously
traffic into these areas by a CXCL13-dependent pathway (42).
Following activation, they migrate to regional lymph nodes and
intestinal lamina propria (26, 43). The accumulation of IL-17-
producingB1 cells inmediastinal lymphnodes following infection
reported here may reflect this activation-induced cell trafficking.
Immature plasma cells (plasmablasts) may also express CCD19,
B220, andCD43 and, thus,may also be the B cells producing IL-17
within the mediastinal lymph nodes described here (44). Further
work with genetic marking of distinct lineages will be required to
identify these cells unequivocally. These mediastinal node cells
from P. aeruginosa-infected animals require further stimulation
with P. aeruginosa to expand the population of B1a cells and to
produce secretion of IL-17. This migration and subsequent divi-
sion in response to P. aeruginosa is likely produced via Toll-like
receptor (TLR) stimulation with lipopolysaccharide (LPS) from
the Gram-negative organisms, as has been shown previously (45).
However, given that mice lacking B cells showed no defect in the
incidence of chronic infectionwithP. aeruginosa, these B1 cells are
dispensable as a source of protective IL-17.
Within lung parenchyma following infection, IL-17 was pro-
duced from CD4
 cells with properties of Th17 cells, as well as 
T cells. Both these cell types were increased in the lung following
chronic infection. The generation of P. aeruginosa-specific Th17
cells by a pseudomonal vaccine may thus be of importance in
providing protection against chronic infection.
The P. aeruginosa strains used here were both derived from CF
patients but showed important differences in the model (Fig. 1).
Apart from the known difference in alginate production in the
NH57388A strain, genome sequencing revealed multiple genetic
FIG 4 Characteristics of B cells in lungs of animals instilledwithP. aeruginosa-
laden beads. (a to d) Twoweeks after transtracheal instillation ofP. aeruginosa-
laden agar beads, the lungs were homogenized and cells polyclonally stim-
ulated, extracellularly stained for CD3, B220, and CD43, and then
permeabilized and stained for intracellular IL-17A, followed by flow cytom-
etry. (a, b) Representative plots of the expression of B220 and IL-17A by live
CD3 cell populations. (b) Values above gates represent percentage of total
IL-17A
 cells in each gate. (c, d) Representative plots of expression of IL-17A
andCD43byCD3B220
 cells. (d)Values in quadrants represent percentages
of total cells. Results shown are representative of two separate experiments. (e,
f) Lung sections from animals 2 weeks following infection with NH57388A
were immunostained for B cells using B220 staining (e) or for T cells with
Thy1.2 staining (f). Immunostaining is indicated in red, and boxed areas are
shown enlarged to the right. Nuclei are counterstained green.
FIG 5 Bacterial counts in WT and MT mice following infection. Animals
were infected with theNH57388A strain. Each symbol represents the result for
an individual animal; lines indicate median values. P value for comparison
between the groups was determined by Mann Whitney test.
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differences between this strain and YH5 (see Fig. S1 in the supple-
mental material). The alginate overproduction in NH57388A is
due to a deletion of part of themucA gene, which encodes aMucA
anti-sigma factor (22). Also of interest is that YH5 has lost the
genetic machinery necessary to synthesize pyocyanin. This could
account for its relative lack of virulence compared to that of the
NH57388A strain in the IL-17RA knockout animals, but further
work will be required to determine which of these genetic differ-
ences are most important.
Chronic P. aeruginosa infection is a significant problem not
only inCFbut also inCOPD(46) andnon-CFbronchiectasis (47).
Delaying the onset of chronic infection in such patient groups
would represent a very valuable therapeutic goal. Antibiotics can
delay this progression but cannot prevent this transition. A num-
ber of vaccines against P. aeruginosa have been developed to at-
tempt to prevent chronic infection; as yet, none of these have
shown clinical efficacy (48). The work described here opens a new
perspective on the prevention and treatment of such P. aeruginosa
infection. Potential therapies based on augmenting IL-17 ac-
tion—through vaccination or otherwise—could be of great value
in delaying or preventing chronic P. aeruginosa infection in
chronic lung disease.
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